Logos Global Management Reports 5.6% Stake in Avalo Therapeutics, Inc.

On April 1, 2026, Logos Global Management LP and its affiliates, including Logos Global Master Fund LP and Dr. William Arsani, filed a Schedule 13G regarding their stake in Avalo Therapeutics, Inc. (AVTX). The reporting group disclosed beneficial ownership of 1,285,000 shares of Common Stock, representing a 5.6% ownership interest in the company. This position consists of 285,000 shares of Common Stock and options to acquire an additional 1,000,000 shares. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. Dr. William Arsani, as a control person of the various Logos entities, shares voting and dispositive power over the reported securities. The calculation of the ownership percentage is based on 22,788,452 shares outstanding as of March 18, 2026. This filing marks a new significant holding for the group, surpassing the 5% threshold as of the event date on March 26, 2026.